The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Open accessAbstract
Background: Asthma exacerbations are major causes of morbidity in urban children and have significant short- and long-term consequences. Eosinophilic phenotype-directed therapies reduce asthma exacerbations in adults, but limited data are available in children and diverse populations. Furthermore, the molecular mechanisms underlying exacerbations prevented and persistent with immune-based therapies are not well understood. Methods: Urban children and adolescents (6-17 years) living in disadvantaged neighborhoods (n=290) with exacerbation-prone asthma (2+ exacerbations in previous year) and blood eosinophils ≥150 cells/mm3 were randomized 1:1 to mepolizumab (6-11 years: 40 mg; 12-17 years: 100 mg) or placebo injections every 4 weeks added to guideline-based care for 52 weeks. The primary outcome was the number of asthma exacerbations treated with systemic corticosteroids. Mechanisms of treatment response were assessed using nasal transcriptomic modular analysis. [ClinicalTrials.gov: NCT03292588] Findings: The annualized rate of asthma exacerbations was 0.96 (95% confidence interval [CI] 0.78-1.17) with mepolizumab and 1.30 (95% CI, 1.08-1.57) with placebo (rate ratio 0.73; 95% CI, 0.56-0.96; p=0.027). There were no significant differences in secondary outcomes, including time to first exacerbation, lung function, or composite asthma severity index (CASI). Baseline nasal airway transcriptomics identified pathways differentially associated with exacerbation risk: 3 eosinophil-associated inflammatory pathways were significantly suppressed by mepolizumab therapy and related to exacerbation risk in placebo-treated participants (p=0.0012-0.015). In contrast, 5 epithelial-associated inflammatory pathways were uniquely related to exacerbation risk in mepolizumab-treated participants (p=0.0035-0.030). Interpretation: Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic asthma reduced exacerbations, but did not impact other asthma outcomes. Mepolizumab response was related to pre-treatment expression of specific airway inflammatory pathways. Our evaluation linking clinical responses to airway expression of inflammatory pathways demonstrates the importance of integrated mechanistic assessments of therapeutic responses, particularly in Black and Hispanic children, who are at greatest risk for morbidity and mortality from asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Cited by
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 261
Metadata
- Authors
- Jackson, D. J., Bacharier, L. B., Gergen, P. J., Gagalis, L., Calatroni, A., Wellford, S., Gill, M. A., Stokes, J., Liu, A. H., Gruchalla, R. S., Cohen, R. T., Makhija, M., Khurana Hershey, G. K., O'Connor, G. T., Pongracic, J. A., Sherenian, M. G., Rivera-Spoljaric, K., Zoratti, E. M., Teach, S. J., Kattan, M., Dutmer, C. M., Kim, H., Lamm, C., Sheehan, W. J., Segnitz, R. M., Dill-McFarland, K. A., Visness, C. M., Becker, P. M., Gern, J. E., Sorkness, C. A., Busse, W. W., & Altman, M. C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 400
- Issue
- 10351
- Pages
- 502-511
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4290999808
- Cited by
- 160
- References
- 4
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01198-9
- The paper
- Jackson, D. J., Bacharier, L. B., Gergen, P. J., Gagalis, L., Calatroni, A., Wellford, S., Gill, M. A., Stokes, J., Liu, A. H., Gruchalla, R. S., Cohen, R. T., Makhija, M., Khurana Hershey, G. K., O'Connor, G. T., Pongracic, J. A., Sherenian, M. G., Rivera-Spoljaric, K., Zoratti, E. M., Teach, S. J., . . . Altman, M. C. (2022). Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01198-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.